Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: PerkinElmer; Hologic; Accelerate Diagnostics; ATCC

NEW YORK (GenomeWeb) – PerkinElmer laid off 22 employees during the second quarter as a result of a restructuring plan to focus resources on higher growth end markets, the company said in its Form 10-Q filed with the US Securities and Exchange Commission this week. In total PerkinElmer took a pre-tax restructuring charge of $800,000 in its Human Health and Environmental Health segments related to the workforce reductions during Q2. The firm shut down its Signature Genomics business in the second quarter and laid off 17 workers as part of a restructuring effort in Q1.


Hologic said in its Form 10-Q that it expects to record severance and benefit charges of about $3 million for fiscal 2014 related to the relocation of its legacy molecular diagnostics operations to San Diego from Madison, Wis. The move is anticipated to be completed by the end of fiscal 2014, and many of the employees in Madison have been terminated, Hologic said. It expects to record severance and benefit charges totaling $7.1 million, of which it recorded $3.2 million in 2013 and $900,000 in 2012. The San Diego facility had housed Gen-Probe's operations, which Hologic acquired in 2012. Shortly after the completion of the deal, Hologic said it would consolidate its molecular diagnostics business by combining the two facilities.


Accelerate Diagnostics said in its Form 10-Q that it recorded $13,000 in revenues during the second quarter, up 86 percent from $7,000 in the year-ago quarter. All revenues derived from licensing and royalty fees.

For the quarter, the firm's net loss rose to $8.2 million, or $.19 per share, from a net loss of $3.8 million, or $.10 per share, in Q2 2013. Its R&D expenses increased 84 percent year over year to $4.6 million, from $2.5 million, while its SG&A costs nearly tripled to $3.4 million from $1.2 million. Accelerate ended the quarter with $65.2 million in cash and cash equivalents.


ATCC has received ISO 13485:2003 certification for the development, manufacture, and distribution of standards, controls, reagents, and in in vitro diagnostic test kits. Products produced under the certification can be used as controls in molecular diagnostic research, including the development and validation of assays, the detection, evaluation, and analysis of disease status, and the surveillance of infectious agents affecting public health, the company said.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.